Pfizer

Dr. Yvonne Greenstreet has been appointed senior vice president and head of medicines development for Pfizer’s Specialty Care Business Unit. Dr. Greenstreet will assume global responsibility for leading the advancement of the development portfolio and ensuring its alignment with Specialty Care’s strategic objectives. Dr. Greenstreet replaces Dr. Michael Berelowitz, who is retiring from the company. She will report directly to Mr. Germano.

“Yvonne has a strong track record of leadership and outstanding results during her career in the biopharmaceutical industry,” said Geno Germano, president and general manager of Pfizer’s Specialty Care Business Unit. “Her experience in delivering medicines in challenging markets is noteworthy, and she will play an important role in advancing Specialty Care’s commitment to the eradication, remission and relief of serious diseases.”

Dr. Greenstreet joins the company after an 18-year career with GlaxoSmithKline (GSK), where she most recently was senior vice president and chief of strategy, R&D. Her R&D work spans clinical development, medical affairs, health economics, outcomes research, regulatory affairs and portfolio management. At GSK, she was responsible for leading the development of small molecules and biologics in several therapeutic areas, including musculoskeletal, immunology/inflammation, gastrointestinal, urology, ophthalmology and anti-infectives. She had also been responsible for clinical development and medical affairs for GSK’s European business.